To include your compound in the COVID-19 Resource Center, submit it here.

Tolvaptan: Phase II data, Phase III

In a placebo-controlled U.S. Phase II trial in 319 patients, oral tolvaptan significantly decreased body

Read the full 152 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE